Biogen (BIIB) Cash from Operations Growth (1y) (2010 - 2026)
Biogen (BIIB) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -11.73% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 75.53% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 332.04% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 243.47% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 178.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 178.99% |
| Mar 31, 2026 | 148.94% |
| Dec 31, 2025 | -32.72% |
| Sep 30, 2025 | 36.01% |
| Jun 30, 2025 | -74.29% |
| Mar 31, 2025 | -53.13% |
| Dec 31, 2024 | 5,987.20% |
| Sep 30, 2024 | 57.93% |
| Jun 30, 2024 | 28.50% |
| Mar 31, 2024 | 21.50% |
| Dec 31, 2023 | 107.14% |
| Sep 30, 2023 | -10.38% |
| Jun 30, 2023 | -33.88% |
| Mar 31, 2023 | 181.40% |
| Dec 31, 2022 | -120.88% |
| Sep 30, 2022 | -17.92% |
| Jun 30, 2022 | -39.99% |
| Mar 31, 2022 | -78.96% |
| Dec 31, 2021 | 328.36% |
| Sep 30, 2021 | -31.82% |